XETRA - Delayed Quote EUR

Vertex Pharmaceuticals Incorporated (VX1.DE)

419.45

-6.85

(-1.61%)

At close: April 11 at 5:35:43 PM GMT+2

Nasdaq Market Whiplash: 3 Stocks to Buy Hand Over Fist and Hold for Decades

Only a few days ago, the Nasdaq was in a bear market (down 20%-plus from recent all-time highs). What should investors who are experiencing Nasdaq market whiplash do now? Alphabet is now quite reasonably valued with a price-to-earnings-to-growth (PEG) ratio of 1.04, based on data from LSEG.

Motley Fool yesterday

GOOG

COMP

ISRG
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

BOSTON, April 11, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner International Award "for pioneering research into the cellular and molecular mechanisms underlying the genetic disease cystic fibrosis, leading to the development of transformative drug therapies based on these mechanisms, thereby improving and saving countless lives." Negulescu shares the award with Michael

Business Wire 2 days ago

VRTX
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. It recently won approval for a non-opioid pain treatment that could be a game-changer for both patients and the company down the road. Of course, Vertex's success didn't happen overnight -- and the company even had to quickly shift focus after its initial drug, a hepatitis C treatment, didn't deliver lasting growth.

Motley Fool 2 days ago

CRSP

VRTX
Vertex Pharmaceuticals (VRTX) Stock Moves -1.41%: What You Should Know

Vertex Pharmaceuticals (VRTX) reachead $475.49 at the closing of the latest trading day, reflecting a -1.41% change compared to its last close.

Zacks 3 days ago

VRTX

^GSPC
Vertex Pharmaceuticals (VRTX) Surged on Increased Demand for its Cystic Fibrosis (CF) Franchise

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. Markets had a difficult start to 2025; with high levels of volatility in all of the main indices. The Value Fund finished the first quarter +3.0% net of fees and expenses net […]

Insider Monkey 3 days ago

VRTX
We're About to Find Out the Answer to Warren Buffett's Pointed Question About Trump's Tariffs. Here Are 3 Stocks to Buy Depending on What That Answer Is.

Contrary to what you might read on social media, Warren Buffett isn't a fan of tariffs. Berkshire Hathaway even recently took the unusual step of issuing a press release refuting social media claims that Buffett applauded President Trump's economic policies. In an interview with CBS News in March, Buffett called tariffs an "act of war."

Motley Fool 3 days ago

VRTX

AMZN

GOLD
5 Top Growth Stocks to Buy in the Stock Market Sell-Off

Equity markets may be struggling because of President Donald Trump's current economic policies, but that doesn't mean investors should avoid buying stocks right now -- quite the contrary. History tells us that equities tend to experience strong runs following downturns, so it's worth putting money into excellent companies that are being dragged down with along with the broader market. To that end, let's consider five excellent growth-oriented companies to invest in on the dip: Novo Nordisk (NYSE: NVO), Eli Lilly (NYSE: LLY), Vertex Pharmaceuticals (NASDAQ: VRTX), Intuitive Surgical (NASDAQ: ISRG), and Shopify (NASDAQ: SHOP).

Motley Fool 4 days ago

NVO

SHOP

VRTX
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

Zacks 4 days ago

VRTX
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 41% Undervalued

Key Insights Vertex Pharmaceuticals' estimated fair value is US$797 based on 2 Stage Free Cash Flow to Equity Current...

Simply Wall St. 4 days ago

VRTX
Jim Cramer Calls Vertex Pharmaceuticals Incorporated (VRTX) “Terrific” With “Revolutionary Pain Drug”

We recently published a list of Jim Cramer Nailed These 11 Stock Picks. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other stocks that Jim Cramer discusses. On Thursday, April 3rd, the host of Mad Money opened the most recent show by addressing the growing concerns […]

Insider Monkey 5 days ago

VRTX
Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Long Term Growth Stock to Buy According to Billionaires?

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best long term growth stocks to buy according to billionaires. As per Barclays, the US administration announced numerous executive orders […]

Insider Monkey 5 days ago

VRTX
Is Vertex Pharmaceuticals Stock a Buy?

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about 16% from its record high at the time of writing, Vertex shares have outperformed, up 20% year to date. Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is driving record sales.

Motley Fool 5 days ago

VRTX
VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe

With the latest approval, Vertex's Kaftrio is now eligible to treat about 4,000 people living in the EU with rare mutations of cystic fibrosis.

Zacks 5 days ago

VRTX
Vertex to Announce First Quarter 2025 Financial Results on May 5th

BOSTON, April 07, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals First Quarter 2025 Earnings Call."

Business Wire 6 days ago

VRTX
European Commission Approves Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis

LONDON, April 07, 2025--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of people with cystic fibrosis (CF). With this approval, the indication has been expanded to include all patients ages 2 years and older who have at least one non-class I mutation in the cystic fibrosis conductance regulator (CFTR) ge

Business Wire 6 days ago

VRTX
2 Stocks to Buy if You're Worried About a Recession

If a recession does hit, it might also affect the stock market, and different companies and sectors will perform differently. Let's consider two stocks that should handle recessions better than most and are worth investing in for the long haul: Vertex Pharmaceuticals (NASDAQ: VRTX) and HCA Healthcare (NYSE: HCA). Vertex Pharmaceuticals is best known for developing cystic fibrosis (CF) drugs.

Motley Fool 6 days ago

VRTX

HCA
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United Therapeutics (NASDAQ:UTHR).

StockStory 6 days ago

UTHR

BMRN

MRNA
Worried About Trump's New Tariffs? These 3 U.S. Companies Are Set to Weather the Storm

Kroger (NYSE: KR) was one of them. CFO Todd Foley noted in the company's fourth-quarter earnings call last month that Kroger could be affected somewhat by tariffs. Foley singled out Kroger's produce business as the area that could be most affected.

Motley Fool 7 days ago

KR

VRTX
Corporate CFOs Think a Recession Is Coming. Here Are 3 Stocks to Own If They're Right.

The latest CNBC CFO Council Survey found that 60% of CFOs expect a U.S. recession later in 2025. Another 15% predict a recession next year. Ninety percent of the CFOs surveyed believe President Trump's tariffs will cause inflation to rise.

Motley Fool 9 days ago

VRTX

WMT

D
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know

Vertex Pharmaceuticals (VRTX) reachead $484.01 at the closing of the latest trading day, reflecting a +0.11% change compared to its last close.

Zacks 10 days ago

VRTX

Performance Overview

Return	VX1.DE	S&P 500 (^GSPC)
YTD	+8.20%	-8.81%
1-Year	+11.96%	+3.16%
3-Year	+62.96%	+21.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vertex Pharmaceuticals Incorporated (VX1.DE)

Nasdaq Market Whiplash: 3 Stocks to Buy Hand Over Fist and Hold for Decades

Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

Vertex Pharmaceuticals (VRTX) Stock Moves -1.41%: What You Should Know

Vertex Pharmaceuticals (VRTX) Surged on Increased Demand for its Cystic Fibrosis (CF) Franchise

We're About to Find Out the Answer to Warren Buffett's Pointed Question About Trump's Tariffs. Here Are 3 Stocks to Buy Depending on What That Answer Is.

5 Top Growth Stocks to Buy in the Stock Market Sell-Off

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 41% Undervalued

Jim Cramer Calls Vertex Pharmaceuticals Incorporated (VRTX) “Terrific” With “Revolutionary Pain Drug”

Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Long Term Growth Stock to Buy According to Billionaires?

Is Vertex Pharmaceuticals Stock a Buy?

VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe

Vertex to Announce First Quarter 2025 Financial Results on May 5th

European Commission Approves Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis

2 Stocks to Buy if You're Worried About a Recession

Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4

Worried About Trump's New Tariffs? These 3 U.S. Companies Are Set to Weather the Storm

Corporate CFOs Think a Recession Is Coming. Here Are 3 Stocks to Own If They're Right.

Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know

Performance Overview